TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from MYND Life Sciences ( (TSE:MYND) ).
MYND Life Sciences Inc. announced a management cease trade order (MCTO) due to delays in finalizing their annual financial statements for the year ended October 31, 2024, caused by significant restructuring of the company’s debt and equity. The MCTO restricts trading by the CEO and CFO but does not affect other shareholders. The company expects to complete the filings by April 29, 2025, and is currently on the defaulting issuers list of the British Columbia Securities Commission. MYND Life Sciences is working diligently to meet its filing obligations and will provide further updates as necessary.
More about MYND Life Sciences
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, and diagnostics. The company is engaged in developing new biological and chemical entities with unique molecular concepts for psilocybin applications to overcome diseases, advancing pharmaceutical developments through rigorous science and clinical trials while protecting its intellectual property.
YTD Price Performance: 1.67%
Average Trading Volume: 3,175
Technical Sentiment Signal: Sell
Current Market Cap: $2.67M
For detailed information about MYND stock, go to TipRanks’ Stock Analysis page.